- Apollo Biowellness (KOAN, Financial) has re-submitted an application to OTCMarkets.com, pending approval, to regain the ability to file disclosure reports on OTCIQ.
- Once approved, the company will resume filing necessary disclosure statements and financial information.
- Investors can follow Apollo Biowellness updates on X (formerly Twitter) at @ApolloBioKOAN.
Apollo Biowellness, Inc. (OTC Pink: KOAN) has announced the re-submission of its application to OTCMarkets.com to regain the ability to file disclosure reports on OTCIQ. The application is currently under review and awaiting approval from OTCMarkets.com. This move is crucial for the company as it aims to provide transparent financial information to its stakeholders and resume regular disclosure filings.
Company President, James W. Zimbler, stated, "Our application to resume submitting disclosure statements and financial information has been submitted and we are awaiting final approval. As soon as final approval is granted, we will be filing the necessary statements." The company emphasizes its commitment to maintaining transparency and timely communication with its stakeholders through this process.
Apollo Biowellness focuses on the discovery, development, and marketing of biologic-based products, emphasizing regenerative medicine. The company plans to market products designed to mobilize adult stem cells from bone marrow and a dual-acting natural diet aid under third-party label exemptions. Despite the pending approval, investors and stakeholders can track the company's updates and announcements through their X account, formerly Twitter, at @ApolloBioKOAN.
